ASML Stock After Two Guidance Raises: Stronger Earnings, Higher Risks

ASML’s latest results reinforce the company’s position as a critical supplier to advanced semiconductor manufacturing. Second-quarter net sales reached €9.3 billion, net income was €2.9 billion and management lifted 2026 sales guidance to €43 billion–€45 billion, with a 54%–56% gross-margin range.

That is a powerful operating signal, but it is not the same as a low-risk stock entry. After a substantial share-price run-up and with valuation multiples described by market-data providers as roughly 48–56 times earnings, investors need to decide whether future growth can justify the premium.

The guidance upgrades strengthen the earnings case

ASML’s current forecast is materially above its previous €36 billion–€40 billion range. The Q2 result also exceeded the high end of company guidance, helped by stronger Installed Base Management revenue.

The important takeaway is not simply that ASML beat one quarter. The bigger signal is that demand visibility has improved across advanced logic and memory, while customers continue to invest in capacity used for AI-related chips.

That supports a constructive long-term view. However, revenue guidance still depends on converting demand and orders into completed systems, delivered tools and recognized sales. Investors should avoid treating every capacity statement as guaranteed near-term revenue.

Capacity is a competitive advantage—but “booked” is not the same as delivered

ASML plans to increase Low-NA EUV production capacity by roughly 30% in 2027, from a 2026 baseline of about 65 systems. It is also considering a further expansion in 2028, while planning similar growth for immersion-DUV capacity.

Reuters reported that ASML’s capacity could be fully booked through the end of 2027. Other reports describe substantial 2028 orders, but the evidence is less definitive for the claim that all capacity is fully booked through 2028.

That distinction matters. A full order book can support confidence in demand, but investors still need to monitor:

• customer cancellations or delivery deferrals;
• component availability and supplier execution;
• clean-room and production ramp costs;
• the timing of system acceptance and revenue recognition; and
• whether higher output preserves ASML’s targeted margins.

Capacity expansion can reduce the risk that ASML becomes the bottleneck in the AI-chip supply chain. It can also create execution risk if the company expands faster than its suppliers, workforce and customers can absorb.

High-NA EUV offers upside, but adoption will not be synchronized

High-NA EUV is an important long-term growth opportunity, but customer timelines differ. Intel’s use of ASML’s High-NA tools for Panther Lake is evidence of commercial adoption. By contrast, TSMC has reportedly remained cautious about tools costing roughly $400 million and may delay broader deployment.

For ASML, this creates a timing issue rather than an immediate failure of the technology thesis. High-NA could expand the company’s addressable opportunity and increase the value of future leading-edge tools, but the pace of revenue contribution depends on customer process decisions and production schedules.

The next useful evidence will be firm orders, installation milestones and confirmation that customers intend to use High-NA systems in volume—not merely that they are evaluating the technology.

Valuation makes execution more important

ASML’s business quality helps explain why investors accept a premium multiple. Its equipment is central to advanced chip production, and the current outlook points to stronger sales and margins. But a high multiple also raises the cost of disappointment.

At share prices in the mid-$1,700s, market-data sources place the stock at an elevated earnings multiple, although the exact figure varies by provider and earnings basis. The valuation appears to assume several favorable outcomes at once: continued AI-related capital spending, strong utilization, successful capacity expansion, resilient margins and growing High-NA adoption.

Analyst targets remain broadly positive but are far from uniform. MarketBeat lists a $1,970.33 average target, while other providers show averages of $2,199.51 and $2,195.39; individual targets include Wells Fargo at $2,500 and JPMorgan at $2,400.

Those targets demonstrate that analysts see further upside, not that the stock has a built-in margin of safety. Investors should treat them as scenario estimates rather than substitutes for a valuation model.

China remains the clearest downside variable

ASML must also navigate tighter U.S. pressure on semiconductor-equipment exports to China. Reuters identified China policy as a central issue for the company, particularly for DUV tools and the installed base.

Reports also describe Chinese development of immersion-DUV systems, although current production volumes are characterized as negligible. That does not represent an immediate EUV competitive threat, but restrictions on sales and servicing could affect ASML’s systems and installed-base revenue while encouraging longer-term domestic substitution.

The available evidence does not establish the final scope or probability of the proposed MATCH Act, so investors should not treat that proposal as a settled forecast. The practical questions are whether restrictions expand, which tools and services are affected, and how much revenue exposure ASML has in each category.

Institutional buying is not a definitive signal

Recent disclosed holdings show sharply divided institutional activity. Third Point reportedly increased its position by 150%, while Mitsubishi UFJ Asset Management increased its stake by 8.6%. Deepwater Asset Management, by contrast, cut its position by 72.3%; other reports also describe reductions by Deutsche Bank and Coatue.

These transactions do not provide a single consensus view of ASML’s intrinsic value. Disclosed institutional filings are backward-looking snapshots, and individual changes can reflect portfolio construction, risk limits or profit-taking as well as a view on the company’s future.

Fund activity is therefore best used as context—not as a buy or sell trigger.

What to watch before the October 14 earnings report

ASML is scheduled to report third-quarter results on October 14. The most informative indicators will be:

1. Booked capacity by delivery year: Are 2027 and 2028 commitments firm, and are cancellations rising?
2. EUV and DUV production: Is the planned 2027 expansion on schedule without damaging margins?
3. China exposure: What is management’s view of equipment sales, servicing and potential policy changes?
4. Gross margin: Can the company maintain its 54%–56% 2026 target while investing in additional capacity?
5. High-NA demand: Which customers have firm orders, and when do they expect volume production?
6. Demand quality: How much of the Q2 strength came from systems versus Installed Base Management revenue?

A report that confirms firm bookings, disciplined execution and resilient margins could support the premium valuation. Merely meeting the raised guidance may be less impressive if expectations have already moved higher.

Bottom line

ASML looks stronger operationally than it did before the latest guidance increases. The €43 billion–€45 billion 2026 sales outlook, Q2 profitability and planned capacity growth support a favorable long-term thesis.

The investment decision is more balanced at the current valuation. For existing shareholders, the results support holding a high-quality semiconductor-equipment franchise while monitoring the risks. For new investors, a staged purchase or a better entry price may offer a more attractive risk-reward balance than chasing the rally.

The central question is no longer whether ASML has demand. It is whether the company can convert that demand into timely deliveries, durable margins and broader High-NA adoption while limiting the impact of China-related restrictions.